Marco Meglio

Aprill Lane, US Advocacy Lead for Rare Disease at UCB, discusses a new national initiative aimed at improving nutrition access and reducing daily disease burden for patients with myasthenia gravis.

Neurologist Michael Levy, MD, PhD, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is dyskinesia treatment options!

Single-patient study reports reductions in Alzheimer-related biomarkers following dapsone-based therapy for chronic Lyme disease, highlighting a potential but unproven infection–neurodegeneration link.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Greg Pontone, MD, MHS. [LISTEN TIME: 18 minutes]

FDA clears AXS-05 to ease Alzheimer dementia agitation, offering an oral option that significantly delays symptom relapse in long-term data.

Amy Waldman, MD, associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, breaks down phase 1–3 data showing zilganersen’s potential to modify disease progression in Alexander disease.

The associate professor of neurology at the Perelman School of Medicine at the University of Pennsylvania discussed pivotal data on zilganersen, highlighting its efficacy, safety, and potential as the first disease-modifying therapy for Alexander disease.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.

Jaime Ramos, PhD, Assistant Professor of Psychiatry and Neurology at NYU Grossman School of Medicine, discussed the role of neutrophil-to-lymphocyte ratio as a scalable inflammatory marker associated with future dementia risk.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.

Phase 3 data presented at AAN 2026 show that IVIG improves response rates in patients with autoimmune encephalitis refractory to steroids, supporting its role as a second-line immunotherapy option.

New pharmacokinetic data presented at AAN 2026 show that adolescents with focal epilepsy achieve cenobamate exposures comparable to adults, supporting simplified fixed-dose strategies and informing future pediatric development.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the MOGAD pipeline!

A national survey presented at AAN 2026 revealed significant gaps between patients with epilepsy and clinicians in seizure expectations, treatment decisions, and communication around risks like SUDEP.

Edith Graham, MD, assistant professor of neurology at Northwestern Feinberg School of Medicine, discussed diagnostic challenges and induction therapy outcomes in primary CNS vasculitis.

A phase 1b/2 trial presented at AAN 2026 showed HS-10506, a selective OX2R antagonist, significantly improved sleep latency and overall sleep outcomes in adults with insomnia.

A phase 3, double-blind study is assessing telitacicept in generalized myasthenia gravis, following prior trials that demonstrated substantial improvements in functional and strength-based clinical outcomes.

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

Week-52 data from the phase 3 MINT trial show sustained improvements in MG-ADL and QMG scores with inebilizumab in patients with AChR-positive generalized myasthenia gravis.

Phase 2/3 LIBRA trial design evaluates basimglurant, an mGluR5 modulator, using a randomized withdrawal approach to assess durability of pain control and safety in adults with trigeminal neuralgia.

Phase 3 EPIC trial design highlights NRTX-1001 cell therapy as a potential single-administration approach to achieving durable seizure reduction in drug-resistant MTLE.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric strokes!

Phase 3 data presented at AAN 2026 show fremanezumab significantly reduces monthly migraine days in pediatric episodic migraine but not chronic migraine.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Julie Kurek, MD. [LISTEN TIME: 25 minutes]

The FDA has cleared an updated Cala kIQ Plus wearable system, adding adaptive features to support personalized management of hand tremor in essential tremor and Parkinson disease.

The director of neurointerventional surgery at Abbott Northwestern Hospital, part of Allina Health, discussed evolving stroke care, patient selection, and emerging neurointerventional technologies shaping clinical practice.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Alexander Shustorovich, DO, an interventional pain medicine physician, discussed a unique case of sustained pain relief after spinal cord stimulation trial and its implications for neuromodulation strategies.

Real-world MOGAD data show tocilizumab drives relapse-free control, improves disability and vision, but requires infection monitoring.